HENRY SCHEIN
NEWS RELEASE
Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747
FOR: Henry Schein, Inc.
CONTACT: Steven Paladino
Executive Vice President and Chief
Financial Officer
steven.paladino@henryschein.com
(631) 843-5500
Susan Vassallo
Director, Investor and
Public Relations
susan.vassallo@henryschein.com
FOR IMMEDIATE RELEASE (631) 843-5562
HENRY SCHEIN FOURTH QUARTER NET SALES UP 26% TO $1.2 BILLION
Diluted EPS of $0.33 after $0.10 charge related to influenza vaccine contract
MELVILLE, N.Y. - March 1, 2005 - Henry Schein, Inc. (Nasdaq NM: HSIC), the
largest provider of healthcare products and services to office-based
practitioners in the combined North American and European markets, today
reported financial results for the quarter ended December 25, 2004. On
January 31, 2005 the Company announced a 2-for-1 stock split, in the form of a
100% stock dividend, which was paid on February 28, 2005 to shareholders of
record as of February 15, 2005. Therefore, share and per-share figures in this
news release are provided on a post-split basis.
Net sales for the fourth quarter of 2004 were a record $1.19 billion,
an increase of 26.1% from the fourth quarter of 2003 (See Exhibit A for details
of sales growth). This increase includes 24.3% local currency growth (9.0%
internally generated and 15.3% from acquisitions) and 1.8% related to foreign
currency exchange.
Fourth quarter net income was $29.6 million and earnings per diluted
share was $0.33. Fourth quarter financial results reflect a pre-tax one-time
charge of $13.2 million ($8.4 million post-tax, or $0.10 per diluted share)
associated with the Company's agreement with Chiron Corporation (Nasdaq
NM: CHIR) to distribute Fluvirin(R) influenza vaccine in 2005. The Company has
recognized this charge in the fourth quarter, in accordance with accounting
rules, due to the significant uncertainty of availability of Fluvirin for 2005,
based solely on public statements and public information. This charge was
described in Henry Schein's third quarter 2004 earnings release dated
October 26, 2004. On a comparable basis, excluding this charge, net income for
the fourth quarter of 2004 was $37.9 million, up 6.7% compared with the fourth
quarter of 2003, and diluted EPS was $0.43, up 10.3% (See Exhibit B for
details).
"Record net sales for the fourth quarter reflect excellent growth in
each of our business groups. Internal growth in local currencies was well ahead
of our estimates for growth in the markets we serve and was complemented by
several strategic acquisitions," said Stanley M. Bergman, Chairman,
Chief Executive Officer and President of
- more -
Henry Schein. "Strong fourth quarter sales growth contributed to
full-year net sales in excess of $4 billion, representing achievement of another
financial milestone for our company."
For the quarter, Dental sales increased by 20.2%, including 19.7%
growth in local currencies (18.0% internally generated and 1.7% from
acquisitions) and 0.5% related to foreign currency exchange. Of the 19.7% local
currency growth, Dental consumable merchandise sales increased 18.5% (17.6%
internal growth) and Dental equipment sales and service revenues were up 22.8%
(19.1% internal growth).
"Internal growth by our Dental Group was more than three times our
estimate for market growth, with continued strength in both consumable
merchandise and equipment sales and service revenues. Sales of the Colgate and
Pentron product lines we introduced in 2004 accounted for about one-half of the
local internal Dental consumable merchandise growth," explained Mr. Bergman.
"Subsequent to the close of the fourth quarter we announced that
Sullivan-Schein Dental was named an authorized dealer for Sirona Dental Systems'
full line of imaging, operatory and handpiece products in the U.S., and we also
announced our acquisition of Canadian full-service dental distributor Ash Temple
Limited. Together with our November 2004 purchase of the full-service regional
dental distributor Barton-Cyker Dental Supply and the prospects for continued
strong internal growth, we are optimistic about further market-share gains by
our Dental Group," he added.
Medical sales increased 2.7% during the fourth quarter, reflecting the
absence of Fluvirin sales. Excluding $35.7 million in Fluvirin sales from the
fourth quarter of 2003, Medical sales growth in the fourth quarter of 2004 was
13.3% (10.2% internal and 3.1% from acquisitions) (See Exhibit C for details).
"Net sales growth in the Medical Group's core alternate care market
during the fourth quarter was 17.0% without the Fluvirin impact, reflecting,
among other factors, our comprehensive offering of products and value-added
services," commented Mr. Bergman. "We have entered into a multi-year agreement
for influenza vaccine with ID Biomedical (Nasdaq NM: IDBE) announced in December
2004, and we are exploring multiple opportunities for sourcing influenza vaccine
in 2005 and beyond, although there can be no assurance that any of the
opportunities will materialize. We look forward to leveraging our proven
expertise and physician relationships in the important influenza vaccine
market."
Technology and Value-Added Services Group sales grew 14.6% (essentially
all internally generated), or 14.2% in local currencies during the quarter.
International Group sales increased 94.1%, including 84.8% in local currencies
(8.9% internally generated and 75.9% from acquisitions) and 9.3% due to foreign
currency exchange.
"Growth in Technology and Value-Added Services revenues reflects
continued strength in our software and electronic services businesses.
International Group internal sales gains in local currencies outpaced our
estimate for market growth by several percentage points, while total
International Group sales growth was significantly bolstered by the acquisition
of the Demedis full-service businesses in Germany and the Benelux countries, and
the KRUGG direct-marketing dental business in Italy. Integrating the acquired
businesses into Henry Schein is proceeding
-more-
according to our plans and we are optimistic about further international
success, particularly in Europe," Mr. Bergman added.
The fourth quarter operating margin decline is reflective of the
absence of Fluvirin sales and the $13.2 million one-time charge related to the
Chiron contract. Cash flow from operations for the fourth quarter of 2004 was
$133.4 million, compared with $110.8 million for the fourth quarter of 2003.
Stock Repurchase Plan
In June 2004 the Company announced a share repurchase program of up to
$100 million worth of common stock, under which 258,810 post-split shares were
repurchased during the fourth quarter at an average price of $30.58 per share.
The impact of the repurchase of shares under this program on fourth quarter
diluted EPS was not meaningful. To date under this program, 1,168,810 post-
split shares have been repurchased at an average price of $31.01 per share.
2005 EPS Guidance
Due to the significant uncertainty of the situation regarding the
availability of Fluvirin influenza vaccine from Chiron, Henry Schein is
providing guidance both excluding and including that product. If Chiron is not
able to re-enter the influenza vaccine market this year, Henry Schein expects
2005 diluted earnings per share in the range of $1.73 to $1.77 post split. This
represents mid-teens percentage diluted EPS growth over 2004, excluding the
$0.10 one-time charge related to the Fluvirin contract. This guidance assumes
no significant increase in sales of other manufacturers' influenza vaccine
products over 2004 levels. Should Henry Schein receive its full allotment of
Fluvirin product for 2005, the Company expects diluted earnings per share in the
range of $2.00 to $2.04 post split. This equals previous guidance, adjusted
only for the stock split.
Henry Schein expects that growth will accelerate during the second half
of 2005 compared with the first half, due to first half expenses associated with
relocation to a new corporate headquarters building, seasonality changes and
integration costs among others. This guidance does not include the impact of
expensing of stock options for the second half of the year (per Financial
Accounting Standards No. 123(R)). The Company noted that all 2005 guidance is
for current operations including completed acquisitions, and does not include
the impact of potential future acquisitions.
Fourth Quarter Conference Call Webcast
The Company will hold a conference call to discuss fourth quarter
financial results today, beginning at 10:00 a.m. Eastern Time. Individual
investors are invited to listen to the conference call over the Internet through
Henry Schein's Web site at www.henryschein.com. In addition, a replay will be
available beginning shortly after the call has ended.
- more -
About Henry Schein
Henry Schein, a Fortune 500(R) company, is recognized for its excellent
customer service and highly competitive prices. The Company's four business
groups - Dental, Medical, International and Technology - serve more than 475,000
customers worldwide, including dental practices and laboratories, physician
practices and veterinary clinics, as well as government and other institutions.
The Company's sales reached a record $4.1 billion in 2004. The Company operates
through a centralized and automated distribution network, which provides
customers in more than 125 countries with a comprehensive selection of over
90,000 national and Henry Schein private-brand products.
Henry Schein also offers a wide range of innovative value-added
practice solutions, including such leading practice management software systems
as DENTRIX(R) and Easy Dental(R) for dental practices, and AVImark(R) for
veterinary clinics, which are installed in over 50,000 practices; and ArubA(R),
Henry Schein's electronic catalog and ordering system.
Headquartered in Melville, N.Y., Henry Schein employs nearly 10,000
people and has operations in 17 countries. For more information, visit the
Henry Schein Web site at www.henryschein.com.
In accordance with the "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995, the Company provides the following
cautionary remarks regarding important factors which, among others, could cause
future results to differ materially from the forward-looking statements,
expectations and assumptions expressed or implied herein. All forward-looking
statements made by us are subject to risks and uncertainties and are not
guarantees of future performance. These forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
Company's actual results, performance and achievements, or industry results to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. These statements are
identified by the use of such terms as "may," "could," "expect," "intend,"
"believe," "plan," "estimate," "forecast," "project," "anticipate" or other
comparable terms. A full discussion of the Company's operations and financial
condition, including factors that may affect its business and future prospects,
is contained in documents the Company has filed with the SEC and will be
contained in all subsequent periodic filings made with the SEC. These documents
identify in detail important risk factors that could cause the Company's actual
performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to
differ materially from current and historical results include, but are not
limited to: competitive factors; changes in the healthcare industry; changes in
government regulations that affect the Company; financial risks associated with
the Company's international operations; fluctuations in quarterly earnings;
transitional challenges associated with acquisitions; regulatory and litigation
risks; the dependence on the Company's continued product development,
technical support and successful marketing in the technology segment; the
Company's dependence upon sales personnel and key customers; the Company's
dependence on its senior management; the Company's dependence on third parties
for the manufacture and supply of its products; possible increases in the cost
of shipping the Company's products or other service trouble with the Company's
third-party shippers; risks from rapid technological change; and risks from
potential increases in variable interest rates.
The order in which these factors appear should not be construed to
indicate their relative importance or priority. The Company cautions that these
factors may not be exhaustive and that many of these factors are beyond the
Company's ability to control or predict. Accordingly, forward-looking
statements should not be relied upon as a prediction of actual results. The
Company undertakes no duty and has no obligation to update forward-looking
statements.
(TABLES TO FOLLOW)
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
THREE MONTHS ENDED YEARS ENDED
-------------------------- --------------------------
DECEMBER 25, DECEMBER 27, DECEMBER 25, DECEMBER 27,
2004 2003 2004 2003
----------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED)
Net sales ............................................ $ 1,194,320 $ 946,924 $ 4,060,266 $ 3,353,805
Cost of sales ........................................ 874,484 693,176 2,983,860 2,426,611
----------- ----------- ----------- -----------
Gross profit .................................. 319,836 253,748 1,076,406 927,194
Operating expenses:
Selling, general and administrative .............. 269,789 194,664 863,319 693,475
----------- ----------- ----------- -----------
Operating income .............................. 50,047 59,084 213,087 233,719
Other income (expense):
Interest income .................................. 1,683 2,236 8,034 8,746
Interest expense ................................. (5,748) (4,171) (18,115) (18,311)
Other, net ....................................... (83) 367 368 1,622
----------- ----------- ----------- -----------
Income before taxes, minority interest,
equity in earnings of affiliates and loss
on sale of discontinued operation ............ 45,899 57,516 203,374 225,776
Taxes on income from continuing operations ........... (16,938) (21,396) (75,404) (84,378)
Minority interest in net loss (income) of subsidiaries 221 (833) (1,486) (2,807)
Equity in earnings of affiliates ..................... 368 255 1,699 931
----------- ----------- ----------- -----------
Net income from continuing operations ................ 29,550 35,542 128,183 139,522
Loss on sale of discontinued operation,
net of tax ........................................ -- -- -- (2,012)
----------- ----------- ----------- -----------
Net income ........................................... $ 29,550 $ 35,542 $ 128,183 $ 137,510
=========== =========== =========== ===========
Earnings from continuing operations per share:
Basic ............................................ $ 0.34 $ 0.41 $ 1.47 $ 1.60
=========== =========== =========== ===========
Diluted .......................................... $ 0.33 $ 0.39 $ 1.43 $ 1.55
=========== =========== =========== ===========
Loss on sale of discontinued operation, net of tax per share:
Basic ............................................ $ -- $ -- $ -- $ (0.03)
=========== =========== =========== ===========
Diluted .......................................... $ -- $ -- $ -- $ (0.02)
=========== =========== =========== ===========
Earnings per share:
Basic ............................................ $ 0.34 $ 0.41 $ 1.47 $ 1.57
=========== =========== =========== ===========
Diluted .......................................... $ 0.33 $ 0.39 $ 1.43 $ 1.53
=========== =========== =========== ===========
Weighted-average common shares outstanding:
Basic ............................................ 86,595 87,435 87,253 87,417
=========== =========== =========== ===========
Diluted .......................................... 88,546 90,089 89,462 89,975
=========== =========== =========== ===========
Note: The above 2004 results reflect a $13.2 million pre-tax ($8.4 million post-
tax) one-time charge, included in selling, general and administrative expenses,
recorded in the fourth quarter of 2004, related to the Company's Fluvirin
contract with Chiron Corporation. The effect that this charge had on diluted EPS
for the three months and year ended December 25, 2004 was $0.10.
5
- more -
HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
DECEMBER 25, DECEMBER 27,
2004 2003
----------- -----------
ASSETS
Current assets:
Cash and cash equivalents .................................................. $ 186,621 $ 157,351
Accounts receivable, net of reserves of $44,852 and $43,203 ................ 554,666 467,085
Inventories ................................................................ 486,494 385,846
Deferred income taxes ...................................................... 28,795 30,559
Prepaid expenses and other ................................................. 174,167 115,643
----------- -----------
Total current assets ............................................... 1,430,743 1,156,484
Property and equipment, net .................................................... 176,103 154,205
Goodwill ....................................................................... 627,215 398,888
Other intangibles, net ......................................................... 129,285 37,551
Investments and other .......................................................... 70,324 72,242
----------- -----------
Total assets ....................................................... $ 2,433,670 $ 1,819,370
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ........................................................... $ 367,213 $ 278,163
Bank credit lines .......................................................... 5,969 6,059
Current maturities of long-term debt ....................................... 3,906 3,253
Accrued expenses:
Payroll and related ..................................................... 89,431 68,214
Taxes ................................................................... 70,970 45,969
Other ................................................................... 156,410 117,530
----------- -----------
Total current liabilities .......................................... 693,899 519,188
Long-term debt ................................................................. 525,682 247,100
Deferred income taxes ........................................................... 66,599 32,938
Other liabilities .............................................................. 28,999 4,494
Minority interest .............................................................. 12,438 11,532
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized,
none outstanding ........................................................ -- --
Common stock, $.01 par value, 120,000,000 shares authorized,
86,650,428 and 87,523,946 outstanding .................................. 867 875
Additional paid-in capital .................................................. 445,573 444,681
Retained earnings ........................................................... 615,265 533,654
Accumulated other comprehensive income ...................................... 44,785 24,999
Deferred compensation ....................................................... (437) (91)
----------- -----------
Total stockholders' equity ......................................... 1,106,053 1,004,118
----------- -----------
Total liabilities and stockholders' equity ......................... $ 2,433,670 $ 1,819,370
=========== ===========
NOTE: Certain prior period amounts have been reclassified to conform with the
current period presentation.
6
- more -
HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
For the Periods Ended December 25, 2004 and December 27, 2003
THREE MONTHS ENDED
--------------------------
2004 2003
----------- -----------
(unaudited) (unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES OF CONTINUING OPERATIONS:
Net income ................................................................. $ 29,550 $ 35,542
Loss on sale of discontinued operation, net of tax .................. -- --
----------- -----------
Net income from continuing operations ...................................... 29,550 35,542
Adjustments to reconcile net income to net cash provided by
operating activities of continuing operations:
Depreciation and amortization ....................................... 18,095 10,887
Provision for losses on trade and other accounts receivable ......... 2,031 2,174
Deferred income taxes ............................................... 10,095 (1,438)
Stock issued to 401(k) plan ......................................... -- --
Undistributed earnings of affiliates ................................ (368) (255)
Minority interest in net income (loss) of subsidiaries .............. (221) 833
Other ............................................................... (2,514) 2,107
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (2,023) 46,130
Inventories ................................................... (18,338) (1,325)
Other current assets .......................................... (18,522) (21,850)
Accounts payable and accrued expenses ......................... 115,635 37,947
----------- -----------
Net cash provided by operating activities
of continuing operations .................................................... 133,420 110,752
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets ................................................. (13,150) (9,933)
Payments for business acquisitions, net of cash acquired .................. 19,654 (1) (50,383)
Payments related to pending business acquisitions ......................... (3,950) --
Purchases of marketable securities ........................................ -- (528)
Proceeds from sales of marketable securities .............................. -- 20,515
Proceeds from maturities of marketable securities ......................... -- 900
Other, including discontinued operation ................................... 3,010 (275)
----------- -----------
Net cash provided by (used in) investing activities ........................... 5,564 (39,704)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt .................................. -- --
Payments for debt issuance costs .......................................... (627) --
Net payments on bank borrowings ........................................... (1,258) (862)
Repayment of debt assumed in business acquisitions ........................ -- --
Principal payments on long-term debt ...................................... (295) (1,481)
Proceeds from issuance of stock upon exercise of stock options ............ 2,172 3,970
Payments for repurchases of common stock .................................. (11,547) (4,027)
Other ..................................................................... 144 (4)
----------- -----------
Net cash provided by (used in) financing activities ........................... (11,411) (2,404)
----------- -----------
Net change in cash and cash equivalents ....................................... 127,573 68,644
Effect of exchange rate changes on cash and cash equivalents .................. (13,923) (4,150)
Cash and cash equivalents, beginning of period ................................ 72,971 92,857
----------- -----------
Cash and cash equivalents, end of period ...................................... $ 186,621 $ 157,351
=========== ===========
YEARS ENDED
--------------------------
2004 2003
----------- -----------
CASH FLOWS FROM OPERATING ACTIVITIES OF CONTINUING OPERATIONS:
Net income ................................................................. $ 128,183 $ 137,510
Loss on sale of discontinued operation, net of tax .................. -- 2,012
----------- -----------
Net income from continuing operations ...................................... 128,183 139,522
Adjustments to reconcile net income to net cash provided by
operating activities of continuing operations:
Depreciation and amortization ....................................... 51,326 36,843
Provision for losses on trade and other accounts receivable ......... 3,820 6,548
Deferred income taxes ............................................... 13,294 5,524
Stock issued to 401(k) plan ......................................... 2,805 2,300
Undistributed earnings of affiliates ................................ (1,699) (931)
Minority interest in net income (loss) of subsidiaries .............. 1,486 2,807
Other ............................................................... 1,519 2,005
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable ........................................... (35,075) (69,543)
Inventories ................................................... (28,614) (28,781)
Other current assets .......................................... (13,919) (16,957)
Accounts payable and accrued expenses ......................... 67,873 49,506
----------- -----------
Net cash provided by operating activities
of continuing operations .................................................... 190,999 128,843
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets ................................................. (37,837) (38,978)
Payments for business acquisitions, net of cash acquired .................. (132,375) (118,180)
Payments related to pending business acquisitions ......................... (17,439) --
Purchases of marketable securities ........................................ -- (39,667)
Proceeds from sales of marketable securities .............................. 14,472 40,619
Proceeds from maturities of marketable securities ......................... -- 39,030
Other, including discontinued operation ................................... 627 (946)
----------- -----------
Net cash provided by (used in) investing activities ........................... (172,552) (118,122)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt .................................. 240,000 --
Payments for debt issuance costs .......................................... (5,781) --
Net proceeds payments on bank borrowings .................................. (7,339) (180)
Repayment of debt assumed in business acquisitions ........................ (135,718) --
Principal payments on long-term debt ...................................... (3,359) (8,667)
Proceeds from issuance of stock upon exercise of stock options ............ 21,425 22,348
Payments for repurchases of common stock .................................. (82,213) (61,754)
Other ..................................................................... (645) (122)
----------- -----------
Net cash provided by (used in) financing activities ........................... 26,370 (48,375)
----------- -----------
Net change in cash and cash equivalents ....................................... 44,817 (37,654)
Effect of exchange rate changes on cash and cash equivalents .................. (15,547) (5,646)
Cash and cash equivalents, beginning of period ................................ 157,351 200,651
----------- -----------
Cash and cash equivalents, end of period ...................................... $ 186,621 $ 157,351
=========== ===========
- ----------
(1) Reflects $32.4 million received in October 2004 in connection with the
divestiture and subsequent resale of DentalMV GmbH, as previously disclosed
in the Company's Q3 2004 Form 10-Q, which was treated as a reduction of
purchase price of the Demedis Group acquired in June 2004.
NOTE: Certain prior period amounts have been reclassified to conform with
the current period presentation.
7
- more -
EXHIBIT A
HENRY SCHEIN, INC.
2004 FOURTH QUARTER AND FULL YEAR
SALES GROWTH RATE SUMMARY
(UNAUDITED)
Q4 2004 OVER Q4 2003
-------------------------------------------------------------------------
CONSOLIDATED DENTAL MEDICAL INTERNATIONAL TECHNOLOGY
------------ ----------- ------------ ------------- ------------
Internal 9.0% 18.0% -0.2% 8.9% 14.0%
Acquisitions 15.3% 1.7% 2.9% 75.9% 0.2%
Divestiture -- -- -- -- --
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 24.3% 19.7% 2.7% 84.8% 14.2%
Foreign Currency Exchange 1.8% 0.5% -- 9.3% 0.4%
------------ ----------- ------------ ------------- ------------
TOTAL SALES GROWTH 26.1% 20.2% 2.7% 94.1% 14.6%
============ =========== ============ ============= ============
FULL YEAR 2004 OVER FULL YEAR 2003
-------------------------------------------------------------------------
CONSOLIDATED DENTAL MEDICAL INTERNATIONAL TECHNOLOGY
------------ ----------- ------------ ------------- ------------
Internal 7.5% 14.1% 1.0% 6.5% 10.4%
Acquisitions 12.1% 2.8% 7.1% 47.2% 1.9%
Divestiture -0.6% -- -- -3.7% --
------------ ----------- ------------ ------------- ------------
Local Currency Sales Growth 19.0% 16.9% 8.1% 50.0% 12.3%
Foreign Currency Exchange 2.1% 0.5% -- 11.0% 0.2%
------------ ----------- ------------ ------------- ------------
TOTAL SALES GROWTH 21.1% 17.4% 8.1% 61.0% 12.5%
============ =========== ============ ============= ============
8
- more -
EXHIBIT B
HENRY SCHEIN, INC.
2004 FOURTH QUARTER AND FULL YEAR
DETAILS OF "COMPARABLE BASIS" GROWTH COMPARISON
INCOME STATEMENT SUMMARY
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
FOURTH QUARTER % FULL YEAR %
2004 2003 GROWTH 2004 2003 GROWTH
As Reported
- -----------------------------------------------------------------------------------------------------------------------------------
Net Sales $1,194,320 $946,924 26.1% $4,060,266 $3,353,805 21.1%
Operating Income 50,047 59,084 -15.3% 213,087 233,719 -8.8%
Margin 4.2% 6.2% -205 bp 5.2% 7.0% -172 bp
Net Income from Continuing Operations $29,550 $35,542 -16.9% $128,183 $139,522 -8.1%
Diluted EPS from Continuing Operations 0.33 0.39 -15.4% 1.43 1.55 -7.7%
Net Income $29,550 $35,542 -16.9% $128,183 $137,510 -6.8%
Diluted EPS 0.33 0.39 -15.4% 1.43 1.53 -6.5%
- -----------------------------------------------------------------------------------------------------------------------------------
Add: One Time Charge Related to Influenza
Vaccine Contract (1)
Net Sales -- -- -- --
Operating Income $13,246 -- $13,246 --
Net Income from Continuing Operations 8,358 -- 8,358 --
Diluted EPS from Continuing Operations 0.10 -- 0.10 --
Net Income 8,358 -- 8,358 --
Diluted EPS 0.10 -- 0.10 --
Subtract: Gain on Real Estate Transactions (2)
Net Sales -- -- -- --
Operating Income -- -- -- --
Net Income from Continuing Operations -- -- -- $ (454)
Diluted EPS from Continuing Operations -- -- -- (0.00)
Net Income -- -- -- (454)
Diluted EPS -- -- -- (0.00)
Comparable Basis
- -----------------------------------------------------------------------------------------------------------------------------------
Net Sales $1,194,320 $946,924 26.1% $4,060,266 $3,353,805 21.1%
Operating Income 63,293 59,084 7.1% 226,333 233,719 -3.2%
Margin 5.3% 6.2% -94 bp 5.6% 7.0% -139 bp
Net Income from Continuing Operations $37,908 $35,542 6.7% $136,541 $139,068 -1.8%
Diluted EPS from Continuing Operations 0.43 0.39 10.3% 1.53 1.55 -1.3%
Net Income $37,908 $35,542 6.7% $136,541 $137,056 -0.4%
Diluted EPS 0.43 0.39 10.3% 1.53 1.53 0.0%
- -----------------------------------------------------------------------------------------------------------------------------------
(1) In the fourth quarter of 2004, there was a $13.2 million pre-tax ($8.4
million post-tax) one time charge associated with an agreement with Chiron
Corporation to distribute Fluvirin influenza vaccine. This one-time charge
was included in the "Selling, general and administrative" expense line on
the statements of income.
(2) In the first quarter of 2003, there was a $726 thousand pre-tax ($454
thousand post-tax) gain related to a real estate transaction. This gain was
included in the "Other, net" line on the statements of income.
USE OF NON-GAAP MEASURES: The above information includes financial measures that
are not calculated and presented in accordance with accounting principles
generally accepted in the United States ("GAAP"). The above table reconciles
operating income from continuing operations, net income and diluted earnings per
share, the Company's most directly comparable measure calculated and presented
in accordance with GAAP, to comparable amounts as adjusted to eliminate the
effect of one-time items.
Management eliminated the effect of such one-time items to assist in evaluating
the underlying operational performance of the Company's business, excluding such
one-time items, over the periods presented. Management believes that this
presentation is appropriate and facilitates such an evaluation by management,
investors and analysts. This measure should be considered supplemental to, and
not a substitute for or superior to, financial measures calculated in accordance
with GAAP.
9
-more-
EXHIBIT C
HENRY SCHEIN, INC.
2004 FOURTH QUARTER AND FULL YEAR
MEDICAL SALES GROWTH COMPARISON
NET SALES BY CATEGORY
(IN THOUSANDS)
(UNAUDITED)
Fourth Quarter % Growth
--------------------------- ---------------------------------------
2004 2003 Total Internal Acquisition
---------- ---------- ------- ---------- -------------
Medical Net Sales $390,383 $380,175 2.7% -0.2% 2.9%
Subtract: Fluvirin Sales(1) -- 35,701
Medical Net Sales Excluding Fluvirin $390,383 $344,474 13.3% 10.2% 3.1%
Full Year % Growth
--------------------------- ---------------------------------------
2004 2003 Total Internal Acquisition
---------- ---------- ------- ---------- -------------
Medical Net Sales $1,446,060 $1,338,084 8.1% 1.0% 7.1%
Subtract: Fluvirin Sales(1) -- 130,155
Medical Net Sales Excluding Fluvirin $1,446,060 $1,207,929 19.7% 11.9% 7.8%
- ----------
(1) 2004 financial results were adversely impacted by the absence of Fluvirin
influenza vaccine in 2004, as previously announced.
USE OF NON-GAAP MEASURES
The above 'Medical Sales Growth Comparison' net sales excluding Fluvirin is a
financial measure that is not calculated and presented in accordance with
accounting principles generally accepted in the United States ("GAAP"). The
above table reconciles medical net sales, the Company's most directly comparable
measure calculated and presented in accordance with GAAP, to 'medical net sales
excluding Fluvirin' as adjusted to eliminate the effect of 2003 Fluvirin sales.
Management eliminated the effect of 2003 Fluvirin sales to assist in evaluating
the underlying operational performance of the Company's medical business,
excluding Fluvirin, over the periods presented. Management believes that this
presentation is appropriate and facilitates such an evaluation by management,
investors and analysts. This measure should be considered supplemental to, and
not a substitute for or superior to, financial measures calculated in accordance
with GAAP.
10
###